Page 350 - Basic _ Clinical Pharmacology ( PDFDrive )
P. 350

336     SECTION IV  Drugs with Important Actions on Smooth Muscle


                 collagen, and by epinephrine. Because their effects are reversible   numerous experimental and clinical investigations have shown that
                 within the typical dosing interval, nonselective NSAIDs (eg, ibu-  the PGE compounds and their analogs protect against peptic ulcers
                 profen) do not reproduce this effect, although naproxen, because   produced by either steroids or NSAIDs. Misoprostol is an orally
                 of its variably prolonged half-life, may provide antiplatelet benefit   active synthetic analog of PGE .  The FDA-approved indication
                                                                                             1
                 in some individuals. Not surprisingly, given the absence of COX-2   is for prevention of NSAID-induced peptic ulcers. This and other
                 in platelets, selective COX-2 inhibitors do not alter platelet TXA    PGE analogs (eg, enprostil) are cytoprotective at low doses and
                                                                 2
                 biosynthesis and are not platelet inhibitors. However, COX-  inhibit gastric acid secretion at higher doses. Because it is also an
                 2-derived PGI  generation is substantially suppressed during selec-  abortifacient, misoprostol is a pregnancy category X drug. Miso-
                           2
                 tive COX-2 inhibition, removing a restraint on the cardiovascular   prostol use is low, probably because of its adverse effects including
                 action of TXA , and other platelet agonists. It is highly likely that   abdominal discomfort and occasional diarrhea. Dose-dependent
                           2
                 selective depression of PGI  generation explains the increase in   bone pain and hyperostosis have been described in patients with
                                      2
                 vascular events, particularly major coronary events, in  humans   liver disease who were given long-term PGE treatment.
                 treated with a coxib or nonselective NSAID. High-dose ibuprofen   Selective COX-2 inhibitors were developed in an effort to spare
                 may confer a similar risk, whereas high-dose naproxen appears to   gastric COX-1 so that the natural cytoprotection by locally synthe-
                 be neutral with respect to thrombotic risk. All NSAIDs appear to   sized PGE  and PGI  is undisturbed (see Chapter 36). However,
                                                                             2
                                                                                     2
                 increase the risk of heart failure.                 this benefit is seen only with highly selective inhibitors and is offset,
                   Large clinical studies have now clearly demonstrated secondary   at least at a population level, by increased cardiovascular toxicity.
                 prevention of adverse cardiovascular events (ie, preventing a sec-
                 ond event after an initial event) by low-dose aspirin. There is also   Immune System
                 some evidence that low-dose aspirin can confer primary cardiovas-
                 cular protection (protection from an initial cardiovascular event),   Cells of the immune system contribute substantially to eicosanoid
                 particularly in high cardiovascular risk populations. However,   biosynthesis during an immune reaction. T and B lymphocytes are
                 low-dose aspirin also elevates the low risk of serious gastrointes-  not primary synthetic sources; however, they may supply arachi-
                 tinal bleeding about twofold over placebo. The effects of aspirin   donic acid to monocyte-macrophages for eicosanoid synthesis. In
                 on platelet function are discussed in greater detail in Chapter 34.  addition, there is evidence for eicosanoid-mediated cell-cell inter-
                                                                     action by platelets, erythrocytes, leukocytes, and endothelial cells.
                 Respiratory System                                     PGE  and PGI  limit T-lymphocyte proliferation in vitro, as do
                                                                                   2
                                                                           2
                                                                     corticosteroids. PGE  also inhibits B-lymphocyte differentiation
                                                                                     2
                 PGE  is a powerful bronchodilator when given in aerosol form.   and the antigen-presenting function of myeloid-derived cells, sup-
                    2
                 Unfortunately, it also promotes coughing, and an analog that   pressing the immune response. T-cell clonal expansion is attenuated
                 possesses only the bronchodilator properties has been difficult to   through inhibition of interleukin-1 and interleukin-2 and class II
                 obtain.                                             antigen expression by macrophages or other antigen-presenting
                   PGF   and TXA  are both strong bronchoconstrictors and   cells. The leukotrienes, TXA , and platelet-activating factor stimu-
                                2
                       2α
                                                                                          2
                 were once thought to be primary mediators in asthma. Polymor-  late T-cell clonal expansion. These compounds stimulate the forma-
                 phisms in the genes for PGD  synthase, both DP receptors, and   tion of interleukin-1 and interleukin-2 as well as the expression of
                                       2
                 the TP receptor have been linked with asthma in humans. DP   interleukin-2 receptors. The leukotrienes also promote interferon-γ
                 antagonists, particularly those directed against DP , are being   release and can replace interleukin-2 as a stimulator of interferon-γ.
                                                        2
                 investigated as potential treatments for allergic diseases includ-  PGD  induces chemotaxis and migration of  Th2 lymphocytes.
                                                                         2
                 ing  asthma.  However,  the  cysteinyl  leukotrienes—LTC ,  LTD ,   These in vitro effects of the eicosanoids agree with in vivo findings
                                                           4
                                                                 4
                 and LTE —probably dominate during asthmatic constriction of   in animals with acute organ transplant rejection.
                       4
                 the airways. As described in Chapter 20, leukotriene-receptor
                 inhibitors (eg, zafirlukast, montelukast) are effective in asthma.   A. Inflammation
                 A lipoxygenase inhibitor (zileuton) has also been used in asthma   Aspirin has been used to treat arthritis of all types for approxi-
                 but is not as popular as the receptor inhibitors. It remains unclear   mately 100 years, but its mechanism of action—inhibition of
                 whether leukotrienes are partially responsible for acute respiratory   COX activity—was not discovered until 1971. COX-2 appears
                 distress syndrome.                                  to be the form of the enzyme most associated with cells involved
                   Corticosteroids and cromolyn are also useful in asthma. Corti-  in the inflammatory process, although, as outlined above, COX-1
                 costeroids inhibit eicosanoid synthesis and thus limit the amounts   also contributes significantly to prostaglandin biosynthesis during
                 of eicosanoid mediator available for release. Cromolyn appears   inflammation. Aspirin and other anti-inflammatory agents that
                 to inhibit the release of eicosanoids and other mediators such as   inhibit COX are discussed in Chapter 36.
                 histamine and platelet-activating factor from mast cells.
                                                                     B. Rheumatoid Arthritis
                 Gastrointestinal System                             In rheumatoid arthritis, immune complexes are deposited in the
                 The  word  “cytoprotection” was  coined  to signify  the  remarkable   affected joints, causing an inflammatory response that is amplified
                 protective effect of the E prostaglandins against peptic ulcers in   by eicosanoids. Lymphocytes and macrophages accumulate in the
                 animals  at  doses that  do  not  reduce  acid  secretion.  Since  then,   synovium, whereas leukocytes localize mainly in the synovial fluid.
   345   346   347   348   349   350   351   352   353   354   355